- 7 oral displays and 1 e-poster highlighting Lunit’s most recent analysis on its AI resolution for radiology, have been accepted by RSNA
- Program will embrace research evaluating the efficiency of Lunit’s business AI software program throughout large real-world inhabitants teams
- Software program now clinically utilized in greater than 1,000 world medical websites
SEOUL, South Korea, Nov. 1, 2022 /PRNewswire/ — Lunit (KRX: 328130.KQ), a number one world supplier of AI-powered most cancers options, right now introduced will probably be returning to the Radiological Society of North America to attend the 108th Scientific Meeting and Annual Assembly (RSNA 2022), to be held from Nov. 27 – Dec. 1. The corporate will current 8 abstracts highlighting its most recent analysis on the Lunit INSIGHT suite, an AI resolution for radiology.
Since 2016, the corporate has continued to current findings yearly at RSNA based mostly on its most mature merchandise for radiology—Lunit INSIGHT CXR, an AI resolution for chest x-ray, and Lunit INSIGHT MMG, an AI resolution for mammography. Lunit has since introduced upgraded variations of the 2 software program, now clinically obtainable in 1,000 medical websites throughout greater than 40 nations.
Final yr, Lunit additionally showcased a demo model of its brand-new AI resolution for Digital Breast Tomosynthesis (Lunt INSIGHT DBT), signaling its growth of the Lunit INSIGHT product line.
This yr’s program will characteristic 7 oral displays together with research that aimed to judge the efficiency of Lunit’s business AI suite for radiology throughout large real-world inhabitants teams.
Shows based mostly on Lunit INSIGHT CXR will embrace an investigation of the medical influence of implementing an AI CXR CAD system on the referral price to chest CT, in addition to a research aimed to judge the efficacy of a deep learning-based chest CT registration mannequin for pulmonary nodule interval adjustments.
Shows that includes Lunit INSIGHT MMG will embrace an analysis of AI as an impartial reader for screening mammograms, a research measuring the influence of downsampling of digital mammography photographs on AI most cancers detection, and a research evaluating the efficiency of the Lunit INSIGHT MMG and Lunit INSIGHT DBT.
“Lunit is proud to announce that 7 out of our 8 analysis research have been chosen for oral presentation at RSNA this yr—a significant breakthrough within the tutorial recognition of the creating medical AI subject,” stated Lunit CEO Brandon Suh. “We plan on using this yr’s assembly to actively work together with our enterprise companions and guests.”
Lunit at RSNA 2022
Go to sales space #4939 for product demonstrations of the Lunit INSIGHT suite. Out there from Nov. 27 – Nov. 30, 10:00 AM to five:00 PM.
With AI, Lunit goals to ‘conquer most cancers,’ one of many main causes of dying worldwide. Lunit is an AI software program firm dedicated to creating AI options for precision diagnostics and therapeutics, to search out the best analysis on the proper price, and the best remedy for the best sufferers. Lunit, a portmanteau of ‘studying unit,’ is a deep learning-based medical AI firm dedicated to creating superior medical picture analytics and data-driven imaging biomarkers by way of cutting-edge expertise.
Based in 2013, Lunit has been acknowledged across the globe for its superior, state-of-the-art expertise and its software in medical photographs. Our expertise has been acknowledged at worldwide AI competitions surpassing prime firms like Google, IBM, and Microsoft. As a medical AI firm that values constructing medical proof, our findings are introduced in main peer-reviewed journals and world conferences together with ASCO and AACR. Lunit is headquartered in Seoul, South Korea with places of work in representatives within the U.S.A., Netherlands, and China.